Moses 2.0 vs Magneto for HoLEP - a Randomized Controlled Trial

June 5, 2026 updated by: Amy Krambeck, Northwestern University

MOSES 2.0 vs Quanta Magneto 150 Holmium Laser for Holmium Laser Enucleation of the prostate-a Randomized Controlled Trial

The objective of this study is to compare the Magneto 150 holmium laser to the current MOSES 2.0 technology to see if there is a benefit in decreased hemostasis time intraoperatively.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The Magneto 150 is a high-powered 150W holmium laser that offers similar pulse-modulation benefits of MOSES 2.0, which facilitates effective dissection and enucleation of the tissue plane while also offering a new first-of-its kind proprietary Magneto setting which allows for very low peak power of 500W and longer pulse duration which allows for better hemostasis.

Study Type

Interventional

Enrollment (Estimated)

180

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Undergoing HoLEP for the treatment of bothersome lower urinary tract symptoms
  • Internet access and a device to complete postoperative questionnaires (smartphone, tablet, laptop or desktop computer)

Exclusion Criteria:

  • Patients who lack decisional capacity
  • Patients unable to read/speak English
  • Patients who are on a blood thinner (anticoagulation medication)
  • Patients who do not have internet access to complete postoperative surveys

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Moses 2.0
HoLEP procedure performed using the Moses 2.0 holmium laser
Device: Moses 2.0 holmium laser
The HoLEP procedure will be performed using the Moses 2.0 holmium laser
Experimental: Magneto 150
HoLEP procedure performed using Magneto 150 holmium laser
Device: Magneto 150 holmium laser
The HoLEP procedure will be performed using the Quanta Magneto 150 holmium laser

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean hemostasis time
Time Frame: During surgery
Overall intraoperative hemostasis time
During surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean (average) enucleation time
Time Frame: During surgery
Time taken to surgically remove excess prostate tissue while leaving the shell of the prostate intact and within the body.
During surgery
Total operative time
Time Frame: During surgery
Time taken from official procedure start to completion (not accounting for the time that the patient is wheeled in, prepped and out of the operating room).
During surgery
Hemostasis efficiency
Time Frame: During surgery
minutes/gram (prostate tissue removed)
During surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Northwestern University

Collaborators

Cook Group Incorporated

Investigators

  • Principal Investigator: Perry Xu, MD, Northwestern University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2026

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

June 1, 2028

Study Registration Dates

First Submitted

June 2, 2026

First Submitted That Met QC Criteria

June 5, 2026

First Posted (Actual)

June 8, 2026

Study Record Updates

Last Update Posted (Actual)

June 8, 2026

Last Update Submitted That Met QC Criteria

June 5, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • STU00225001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Benign Prostatic Hyperplasia

Clinical Trials on Moses 2.0 holmium laser

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe